Welcome to our dedicated page for Spruce Biosciences news (Ticker: SPRB), a resource for investors and traders seeking the latest updates and insights on Spruce Biosciences stock.
Spruce Biosciences, Inc. (SPRB) generates news that centers on its late-stage biopharmaceutical efforts to develop and commercialize therapies for neurological disorders with significant unmet medical need. Company announcements focus heavily on tralesinidase alfa enzyme replacement therapy (TA-ERT) for Sanfilippo Syndrome Type B (MPS IIIB), an ultra-rare, serious, and fatal genetic disease for which Spruce states there are currently no FDA-approved treatments.
News coverage for SPRB commonly includes clinical and regulatory milestones. Examples from company releases include integrated long-term clinical data for TA-ERT, demonstrating profound and durable reductions in cerebral spinal fluid heparan sulfate non-reducing end (CSF HS-NRE) and stabilization of cognition and cortical grey matter volume, as well as the U.S. FDA granting Breakthrough Therapy Designation for TA-ERT and confirming CSF HS-NRE as a surrogate biomarker reasonably likely to predict clinical benefit.
Investors also see financing and capital markets updates in Spruce’s news flow. The company has reported a private placement with institutional investors expected to provide approximately $50.0 million in gross proceeds to advance TA-ERT, and a loan and security agreement with Avenue Venture Opportunities Fund II, L.P. providing access to up to $50.0 million in term loans tied to regulatory and commercial milestones. Additional headlines cover reverse stock split actions, conditional approval and resumption of trading on the Nasdaq Capital Market, and related listing matters.
Corporate governance and pipeline diversification are further themes in SPRB news. Spruce has announced board changes, including the appointment of Keli Walbert to its board of directors and compensation committee, as well as director resignations. The company has also issued updates on tildacerfont, being studied in major depressive disorder under a collaboration with HMNC Holding GmbH, and referenced SPR202 for congenital adrenal hyperplasia. For readers tracking SPRB, this news page provides a centralized view of the company’s clinical progress, regulatory interactions, financing events, and governance developments.
Spruce Biosciences (Nasdaq: SPRB), a late-stage biopharmaceutical company, has announced participation in two investor conferences. CEO Richard King will engage in a fireside chat at the 10th Annual SVB Leerink Global Healthcare Conference on February 24 at 9:00am PST. Additionally, he will take part in a panel discussion on March 2 at the 41st Cowen Annual Healthcare Conference at 11:10am PST. Interested parties can access live webcasts on the company’s website, with replays available for 30 days.
Spruce Biosciences (Nasdaq: SPRB) announced its focus on advancing the CAHmelia program for tildacerfont aimed at treating adults with classic congenital adrenal hyperplasia (CAH). The company plans to initiate a Phase 2 study for pediatric CAH and a rare form of polycystic ovary syndrome (PCOS) in 2021. With approximately $157 million in cash, it aims for major milestones including potential new drug applications. Spruce also bolstered its patent portfolio, extending exclusivity through 2038.
Spruce Biosciences (Nasdaq: SPRB) announced its inclusion in the Russell 2000®, 3000®, and Microcap® Indexes effective December 21, 2020, following quarterly additions by Russell. CEO Richard King highlighted this milestone as a means to enhance visibility and attract institutional investors. The Russell 2000® Index represents around 10% of the total market capitalization of the Russell 3000®. Russell indexes are utilized widely by investment managers, with around $9 trillion in assets tracked against them, indicating a significant recognition for Spruce Biosciences.
Spruce Biosciences, Inc. (Nasdaq: SPRB) reported its Q3 2020 financial results, highlighting significant advancements in its late-stage CAHmelia program for adult classic congenital adrenal hyperplasia (CAH). The company has initiated two studies, CAHmelia-203 and CAHmelia-204, to assess the impact of tildacerfont. Following a successful IPO in October 2020, Spruce reported pro forma cash and equivalents of $168.4 million. However, net losses increased to $9.6 million in Q3 2020 from $2.6 million in Q3 2019, with R&D expenses rising significantly due to clinical development efforts.
SAN FRANCISCO--Spruce Biosciences (Nasdaq: SPRB), a biopharmaceutical company focused on therapies for rare endocrine disorders, will participate in the Credit Suisse 29th Annual Virtual Healthcare Conference. CEO Richard King is scheduled to present on November 12 at 4:15 p.m. EST. Interested parties can access the live audio webcast from the company’s Investor Relations section, with a replay available for 30 days post-event. The company is developing tildacerfont to address classic congenital adrenal hyperplasia, a serious condition with no novel therapies approved in 50 years.
Spruce Biosciences announced the successful closure of its initial public offering, selling 6,900,000 shares at $15.00 each, raising gross proceeds of $103.5 million. The offering included 900,000 shares from underwriters' exercised options. Trading commenced on the Nasdaq Global Select Market on October 9, 2020, under the ticker symbol SPRB. Spruce focuses on developing therapies for rare endocrine disorders, specifically targeting congenital adrenal hyperplasia with its product candidate, tildacerfont.